ImmuCell Q2 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) reported higher second-quarter income and net arsenic home request for its calf scours prevention products increased, portion the institution outlined plans to put astir $8 cardinal to much than triple manufacturing capableness by the extremity of 2027.

Product income roseate 11.5% twelvemonth implicit twelvemonth to $7.2 cardinal successful the 2nd 4th of 2026. For the archetypal six months of the year, merchandise income accrued 20.9% to $17.5 million, according to Chief Financial Officer Timothy C. Fiori.

→ Lumentum Just Delivered the AI Growth Investors Wanted

The institution recorded second-quarter nett income of $1.8 million, oregon $0.20 per share, compared with nett income of $500,000, oregon $0.06 per share, a twelvemonth earlier. Results included a antecedently announced $2 cardinal colony with ImmuCell's erstwhile Re-Tain declaration manufacturer. First-half nett income totaled $3.8 million, compared with $1.9 cardinal successful the prior-year period.

Domestic Growth Offsets International Decline

Domestic second-quarter income accrued 27.7% to $6.2 million, portion planetary income declined 38.9% to astir $1 million. Fiori said the planetary alteration was chiefly attributable to income successful Canada, wherever prior-year results benefited from orders associated with clearing a backorder situation.

→ AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be

President and CEO Olivier te Boekhorst said the company's strategical absorption since precocious 2025 has been connected its First Defense calf scours preventative portfolio. Tri-Shield, the company's flagship product, posted 25.1% maturation during the archetypal fractional of 2026, helium said.

The company's Functional Feed enactment contributed astir 20% of wide first-half growth. U.S. income grew 32.5% successful the archetypal fractional compared with the aforesaid play successful 2025.

→ Joby's Defense Pivot Accelerates With $500M Resonant Sciences Deal

ImmuCell said distributor out-the-door volumes, which it uses arsenic an indicator of income astatine the shaper level, accrued 21% successful the archetypal 4th and 28% successful the 2nd quarter, producing first-half measurement maturation of 24% twelvemonth implicit year.

The institution estimated that First Defense's stock of U.S. animals treated with a biologic scours preventative accrued from astir 15% successful December 2025 to astir 19% astatine the extremity of June. Because First Defense is priced astatine astir doubly the level of competing products, ImmuCell said its stock of shaper spending accrued from astir 29% to 38% implicit that period.

Te Boekhorst attributed the gains successful portion to investments successful the commercialized team, including 3 caller U.S. salespeople. He said the institution sells done organisation partners portion its commercialized enactment focuses connected adding caller shaper customers.